Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 154

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 154
---
 considers control to have transferred upon delivery because the customer has legal title to the asset, physical possession of the asset has been transferred, the customer has significant risks and rewards of ownership of the asset and the Company has a present right to payment at that time.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 15

Disaggregated RevenueThe following table represents disaggregated net product sales in the periods presented as follows (in thousands):Three Months EndedJune 30,Six Months EndedJune 30,2025202420252024Net product sales:   EXPAREL$142,917 $136,852 $279,446 $269,282    ZILRETTA31,334 30,707 54,672 56,546    iovera°5,588 5,674 10,711 10,704    Bupivacaine liposome injectable suspension508 3,154 3,112 5,679       Total net product sales$180,347 $176,387 $347,941 $342,211 

NOTE 5—INVENTORIES

The components of inventories, net are as follows (in thousands):June 30,December 31,20252024Raw materials$40,932 $50,800 Work-in-process11,080 27,384 Finished goods96,151 47,098      Total$148,163 $125,282 In July 2025, the Company announced it decommissioned its 45-liter EXPAREL batch manufacturing suite located at its Science Center Campus in San Diego, California, and reduced its workforce accordingly. As a result, the Company reserved $1.0 million of raw materials during the six months ended June 30, 2025. For more information, see Note 18, Subsequent Events.

NOTE 6—FIXED ASSETS

Fixed assets, net, summarized by major category, consist of the following (in thousands):June 30,December 31,20252024Machinery and equipment$173,729 $160,643 Leasehold improvements97,408 86,034 Computer equipment and software25,232 23,473 Office furniture and equipment1,952 1,952 Construction in progress9,632 27,996         Total307,953